The Mount Sinai Center for Eosinophilic Disorders (MSCED) is a comprehensive center that focuses on the diagnosis, treatment, and research of eosinophilic gastrointestinal disorders (EGIDs), including eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic enteritis (EEnt) and eosinophilic colitis (EC). We are the only center in the tri-state area with a clinical and research focus on EGIDs.
At the MSCED, we believe that patients with EGIDs have specific needs that are best treated by a team approach to management. Working closely together, our team of specialists will help the patient and family determine a diagnosis and set up a treatment plan which can include special diets, medications, and counseling. Our specialists include a gastroenterologist, allergists, pathologists, and a nutritionist. The center also takes part in the EMPOWER program at Mount Sinai, which offers children and their families’ consultations with a psychiatrist to help manage behavioral and emotional issues associated with EGIDs. Patients with EGIDs also have access to the MSCED support group and other educational activities at the Center.
We are dedicated to furthering the knowledge available about EGIDs. Our center spearheads numerous research projects to further understand how these diseases occur, and explore novel therapies for EGIDs through cutting edge medical care, translational research and clinical trials. The MSCED is also proud to be part of CEGIR, and is involved in enrolling patients for CEGIR’s studies.
Related research studies at the MSCED
- A randomized, double-blind, parallel, placebo-controlled study of the efficacy, safety and tolerability of dupilumab in adult patients with active eosinophilic esophagitis- Sponsor: Regeneron Pharmaceuticals, Inc. (NCT02379052)
- Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study- Sponsor: Shire (NCT02605837)
- Development, validation, and evaluation of an adult and pediatric eosinophilic esophagitis activity index: A prospective multicenter study- Sponsor: University of Bern (NCT00939263)
- Developing an Educational Curriculum for Parents of Children with Eosinophilic Esophagitis- Sponsor: Nutricia
- A Study Of The Etiology And Pathogenesis Of Eosinophilic Gastroenteritis- Sponsor: Icahn School of Medicine at Mount Sinai
- A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis (EoE)- Sponsor: Shire (NCT02736409)
- A Phase 3, Multicenter, Open-label Continuation Study with Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects with Eosinophilic Esophagitis (EoE) – Sponsor: Shire (NCT03245840)
- A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis – Sponsor: Allakos Inc. (NCT03664960)
- A Phase 3, Randomized, 3- Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis – Sponsor: Regeneron Pharmaceuticals, Inc. (NCT03633617)
- A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis –Sponsor: Regeneron (NCT04394351)
- Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis -Sponsor: Adare (NCT04281108)
- A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) – Sponsor: AstraZeneca
- A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis- Sponsor: Allakos Inc. (NCT04322708)
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with, Lost Response to, or Were Intolerant to Standard Therapies –Sponsor: Allakos Inc.
- SLC9A3 regulation of esophageal dilated intercellular spaces in EoE Endotypes – Sponsor: NIH- NIAID R01AI140133
- Impact of Proton Pump Inhibitors on the Esophageal Transcriptome in Eosinophilic Esophagitis Subtypes – Sponsor: HOPE APFED/AAAAI Pilot Grant Award
- A Study Of The Etiology And Pathogenesis Of Eosinophilic Gastroenteritis- Sponsor: Icahn School of Medicine at Mount SinaiAn Observational Study Of Children With Eosinophilic Esophagitis And Gastroenteritis- Sponsor: Icahn School of Medicine at Mount Sinai
Mount Sinai Kravis Children’s Hospital Main Website
Mount Sinai Center for Eosinophilic Disorders Website